Results 41 to 50 of about 57,323 (255)

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Cancer Communications, 2019
Background The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational ...
Yuankai Shi, Jin Li, Jianming Xu, Yan Sun, Liwei Wang, Ying Cheng, Wei Liu, Guoping Sun, Yigui Chen, Li Bai, Yiping Zhang, Xiaohui He, Yi Luo, Zhehai Wang, Yunpeng Liu, Qiang Yao, Yuhong Li, Shukui Qin, Xiaohua Hu, Feng Bi, Rongsheng Zheng, Xuenong Ouyang   +21 more
doaj   +1 more source

Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity

Frontiers in Reproductive Health, 2022
Background:Gonadal toxicity following chemotherapy is an important issue among the population of young cancer survivors. The inhibitor of DNA topoisomerase I, irinotecan (CPT-11), is widely used for several cancer types.
Mattan Levi, Mattan Levi, Irit Ben-Aharon, Irit Ben-Aharon, Ruth Shalgi   +4 more
doaj   +1 more source

Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report

Clinical Medicine Insights: Case Reports, 2023
Irinotecan, a topoisomerase I inhibitor, is commonly used in the treatment of advanced colorectal cancer. Its adverse effects include delay diarrhea, severe myelosuppression, and cholinergic-like symptoms.
Yu-Ting Shun, Hsien-Yung Lai, Yi-Ting Chuang, Hsuen-Fu Lin   +3 more
doaj   +1 more source

Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses [PDF]

, 2012
Background: A Phase I dose escalation first in man study assessed maximum tolerated dose (MTD), dose-limiting toxicity (DLT) and recommended Phase II dose of TP300, a water soluble prodrug of the Topo-1 inhibitor TP3076, and active metabolite, TP3011.
Hartley, J.A., MacPherson, I.R.J., Masanori Miwa, Hartley, JM, Jones, K, Crawford Donna, Saito Tomohisa, Evans, TRJ, Hartley, JA, Jones Keith, MacPherson, IRJ, Abe Masaichi, Crawford, D, Jones, K., D Alan Anthoney, John M Hartley, Saito, T., Twelves, C., Hartley Janet A, Anthoney, D.A., Christopher Twelves, Anthoney, DA, Miwa, M., Miwa Masanori, TRJ Evans, Evans, T.R.J., Naik, J, Jay Naik, Donna Crawford, Keith Jones, Abe, M., Saito, T, Tomohisa Saito, Abe, M, Naik Jay, Naik, J., MacPherson Iain RJ, Evans TRJ, Hartley, J.M., Hartley John M, Masaichi Abe, Miwa, M, Twelves, C, Crawford, D., Anthoney D, Janet A Hartley, Twelves Christopher, Iain RJ MacPherson   +47 more
core   +2 more sources

Monitoring of Irinotecan in Human Plasma: Sensitive Fluorescent Nanogels by Molecular Imprinting [PDF]

, 2019
A series of fluorescent molecularly imprinted nanogels to detect irinotecan (CPT11) were prepared and characterized. A set of amino acids and napthalimide polymerisable derivatives allowed to obtain polymers as soluble fluorescent nanoparticles by high ...
Cristina, Forzato, Valentina, Iacuzzi, Paola, Posocco, Martina, Tommasini, Elena, Marangon, Marina, Resmini, Giuseppe, Toffoli, Federico, Berti, Elena, Pellizzoni, Paolo, Bertoncin   +9 more
core   +1 more source

Prediction of novel target genes and pathways involved in irinotecan-resistant colorectal cancer. [PDF]

, 2017
Acquired drug resistance to the chemotherapeutic drug irinotecan (the active metabolite of which is SN-38) is one of the significant obstacles in the treatment of advanced colorectal cancer (CRC).
Chu, CM, Po-Li Wei, Chi-Ming Chu, Wei, PL, Precious Takondwa Makondi, Yu-Jia Chang, Makondi, PT, Chang, YJ   +7 more
core   +1 more source

The Alpha-Lipoic Acid Improves Survival and Prevents Irinotecan-Induced Inflammation and Intestinal Dysmotility in Mice

Pharmaceuticals, 2020
Irinotecan, an anticancer drug, induces diarrhea and intestinal inflammation, resulting in an increase in the cost of care and in treatment delays.
Daniely V. S. Costa, Deiziane V. S. Costa, Caren N. S. Sousa, Angeline M. H. P. Silva, Ingridy S. Medeiros, Dainesy S. Martins, Conceição S. Martins, Ana L. V. Pequeno, Roberto C. P. Lima-Júnior, Pedro M. G. Soares, Silvânia M. M. Vasconcelos, Gerly A. C. Brito, Emmanuel P. Souza   +12 more
doaj   +1 more source

Effect of echinacoside as a palliative for irinotecan-induced intestinal mucositis

Интегративная физиология, 2023
Irinotecan, an anticancer drug, causes severe delayed diarrhea due to its active metabolite, SN-38, which damages the intestinal mucosa. This diarrhea may lead to the discontinuation of anticancer therapy in clinical practice.
Хикару Оцуки, Шизука Джонан, Тайсэй Цудзии, Нахла Хамуда, Кикуко Амагазе   +4 more
doaj   +1 more source

Impact of omega 3 alone or in combination with irinotecan on bone marrow and spleen of rats: in vivo study

Iraqi Journal of Pharmaceutical Sciences, 2023
Objectives: The present study designed to explore the genotoxicity through measurement of Mitotic index in bone marrow and the spleen cells, as possible mechanism of bone marrow and spleen toxicity that induced by irinotecan; and to describe the ...
Alaa Radhi, Nada Al-Shawi, Ali Hassan
doaj   +1 more source

Clinical and molecular factors for selection of nivolumab or irinotecan as third-line treatment for advanced gastric cancer

Therapeutic Advances in Medical Oncology, 2020
Background: The use of nivolumab or irinotecan as the third-line treatment for patients with advanced gastric cancer (AGC) remains controversial. Methods: This study analyzed patients with AGC treated with nivolumab or irinotecan (nivolumab group or ...
Takahiro Ishii, Akihito Kawazoe, Akinori Sasaki, Saori Mishima, Sawada Kentaro, Yoshiaki Nakamura, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Takeshi Kuwata, Genichiro Ishii, Kohei Shitara   +14 more
doaj   +1 more source